<DOC>
	<DOCNO>NCT02556333</DOCNO>
	<brief_summary>Background : HIV attack immune system . Antiretroviral therapy ( ART ) combination drug use treat HIV infection . For people , ART drug stop work HIV . Researchers want see different form drug tenofovir ( ART drug currently approve FDA ) , combine another drug , may help people whose HIV resistant ART . This combination pill call F/TAF Objective : To study safety efficacy drug F/TAF , use ART , people whose HIV infection hard control available medicine . Eligibility : People age 14 year old HIV infection enrol DOTCOM ( 14-I-0009 ) protocol . Design : Participants screen physical exam , medical history , blood urine test . Participants stay hospital least 10 day . For first 9 day , take F/TAF mouth along usual ART drug . In hospital , repeat screening test . Participants DEXA scan , x-ray measure calcium mineral bone . Participants lie soft table scanner pass low spine hip . Participants get supply F/TAF new ART drug take home . Participants follow-up visit 1 , 2 , 4 , 8 , 12 week . After 12-week visit , come back every 3 month 1 year . At visit , participant repeat screen test . They discuss problem take ART drug . They may another DEXA scan .</brief_summary>
	<brief_title>Safety Efficacy Emtricitabine/Tenofovir Alafenamide Part Salvage Antiretroviral Regimens Patients With Uncontrolled Viremia Drug-Resistant HIV Infection</brief_title>
	<detailed_description>Despite success antiretroviral therapy ( ART ) , subset HIV-1-infected patient uncontrolled viremia , multiple drug class resistance , limited treatment option . Tenofovir disoproxil fumarate ( TDF ) form part ART regimens , however long-term use associate renal tubulopathy reduce bone mineral density . Viral mutation ( eg , K65R , multiple thymidine analog mutation ( TAMs ) confer resistance reduce susceptibility TDF . Tenofovir alafenamide ( TAF ) investigational oral prodrug tenofovir . When compare TDF , TAF demonstrate low plasma tenofovir concentration potent antiviral activity approximately one-tenth dose . TAF advantage reduce tenofovir exposure renal tubule bone , potentially result few kidney bone effect . As TDF , TAF potent activity hepatitis B virus ( HBV ) , may treatment option patient HIV/HBV co-infections . Phase 2 trial demonstrate non-inferiority TAF TDF treat HIV-1 infection ART-naive patient . Smaller reduction bone mineral density measure TAF TDF . The common adverse event nausea diarrhea . This single-arm , single-site , open-label trial explore safety efficacy TAF fix combination emtricitabine ( FTC ) ( F/TAF , Gilead Sciences Inc. ) part salvage antiretroviral regimen HIV-1-infected adult adolescent ( great equal 14 year ) experience virologic failure . The study recruit patient fail TDF-containing regimen take TDF ( due resistance mutation risk renal injury ) abacavir/lamivudine ( ABC/3TC ) optimal alternative . Eligible patient begin 9 day inpatient directly observe therapy ( DOT ) F/TAF plus pre-enrollment background regimen . On Day 10 , patient switch F/TAF plus OBT wait result Day 10 HIV RNA result . Patients HIV RNA decline &lt; 0.5 log10 Day 1 Day 10 discontinue F/TAF , end study participation , continue OBT ( TDF/FTC ABC/3TC place F/TAF , appropriate ) 14-I-0009 protocol . Patients great equal 0.5 log10 decline HIV RNA continue F/TAF + OBT 48 week , periodic outpatient assessment adherence , safety , renal function , bone mineral density , HIV RNA , CD4 T cell count . Switching one drug ART regimen due inadequate viral response require inpatient DOT 14-I-0009 .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Viremia</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>INCLUSION Age great equal 14 year Documented HIV1 infection ( write documentation positive standard ELISA rapid HIV1/HIV2 antibody test confirmatory Western Blot , documentation repeat HIV RNA &gt; 1,000 copies/mL ) Concurrent enrollment DOTCOM ( 14I0009 ) protocol For female childbearing potential , willingness use effective contraception duration study Willingness hospitalize 1015 day ( potential day pass ) Willingness blood sample store future research may include genetic test Multiple ART failure define least one follow criterion : HIV RNA &gt; 1000 copies/mL document virologic failure least 1 prior ART regimen least 2 consecutive HIV RNA plasma measurement &gt; 1,000 copies/mL , include last documented value , currently prescribe ART regimen least 6 month ; Documented extensive resistance least 3 antiretroviral ( ARV ) drug class , persistent plasma viremia ( HIV RNA &gt; 1,000 copies/mL &gt; 6 month ) despite multiple regimen change . The patient may enrol even prescribed current regimen le 6 month . Where neither TDF ABC optimal NRTI option define least one follow criterion : Presence M184V mutation plus TDFassociated resistance mutation base genotypic/phenotypic test , specifically K65R alone , TAMs ( 41L , 67N , 70R , 210W , 215Y/F , 219Q/E ) without NRTIassociated mutation ; FTC/TDF consider option due impair renal function ( eGFR CockroftGault equation [ eGFR ( CG ) ] =3060 mL/min ) , risk renal impairment condition uncontrolled hypertension , diabetes mellitus , history renal toxicity receive TDFbased regimen ; ABC/3TC contraindicate ( ie , presence HLA B*5701 allele history hypersensitivity reaction ABC ) , suboptimal option ( eg , presence ABCassociated resistance mutation ( ) patient HBV coinfection ) . EXCLUSION Severe renal impairment ( eGFR ( CG ) &lt; 30 mL/min ) Acute medical illness stem significant comorbidity ( eg , malignancy require chemotherapy , treatment acute opportunistic infection acute renal failture ) . Enrollment may defer 3 month allow condition resolve stabilize . Pregnancy ; however patient becomes pregnant enrol protocol , may continue participation throughout pregnancy . Breastfeeding Concomitant use one follow medication : carbamazepine , oxcarbazepine , phenobarbital , phenytoin , rifabutin , rifampin , rifapentine , bisphosphonate , St. John wort , echinacea , milk thistle , shosaikoto , probenecid . Any illness condition , investigator opinion , may substantially increase risk participation study , compromise scientific objective .</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>August 16, 2016</verification_date>
	<keyword>TAF</keyword>
	<keyword>F/TAF</keyword>
	<keyword>ART</keyword>
	<keyword>TDF</keyword>
	<keyword>DOT</keyword>
</DOC>